Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 7681 results

  1. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  2. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    In development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  4. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    Awaiting development [GID-TA11299] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development [GID-TA10904] Expected publication date: 15 January 2025

    Technology appraisal guidance
    In development

  6. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475

    Awaiting development [GID-TA11586] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Cabozantinib for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment TSID 12078

    Awaiting development [GID-TA11613] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over TS ID 12082

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  11. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399

    Awaiting development [GID-TA11499] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

    Awaiting development [GID-TA11583] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development